Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer
Thomas B. Karasic(Hospital of the University of Pennsylvania), Peter J. O’Dwyer(University of Pennsylvania), Ana De Jesus‐Acosta(Johns Hopkins University), Daniel A. Laheru(Bloomberg (United States)), Colleen Redlinger(University of Pennsylvania), Mark H. O’Hara(University of Pennsylvania), Arturo Loaiza‐Bonilla, Jessica Burrell(University of Pennsylvania), Ursina Teitelbaum(University of Pennsylvania), Erkut Borazanci(HonorHealth), Jeffrey A. Drebin(Memorial Sloan Kettering Cancer Center), Kim A. Reiss(University of Pennsylvania), Daniel D. Von Hoff(Translational Genomics Research Institute), Ravi K. Amaravadi(University of Pennsylvania)
Cited by 289
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k